ClinicalTrials.gg
CompletedNCT02197598Updated Dec 14, 2016

Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use

A Phase 4 interventional study of nalmefene in Alcohol Dependence, sponsored by H. Lundbeck A/S. Completed at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-14.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.

Enrollment
7th of 12
45 · median 212
Started
2014
with 1 other
Phase 4
2 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
5 of 12
H. Lundbeck A/S

Among the 12 studies testing nalmefene in Alcoholism, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is one of 2 in phase 4, and was the 5th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →

About nalmefene

nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing nalmefene in Alcoholism as a file.
02

Study summary

The purpose of this study is to explore the treatment effects of Selincro in alcohol dependent patients with liver impairment.

03

Conditions studied

  • Alcohol Dependence

Keywords

  • nalmefene, alcohol consumption, liver effects
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has alcohol dependence, diagnosed at screening according to ™
  • The patient has had an average alcohol consumption at, at least, a high drinking risk level (that is >60 g of alcohol/day for men and >40 g of alcohol/day for women) in the 4 weeks preceding the Screening Visit and in the period between the Screening and Inclusion Visits (that is, in the Screening Period)
  • The patient has liver impairment defined by elevated liver stiffness and elevated liver enzymes at the Screening Visit (both criteria have to be fulfilled): liver stiffness (LS) as measured by Fibroscan >6 kPa, elevated transaminases ( or ALT). Transaminase levels up to 5 times the upper limit of the reference range and γGT levels up to 10 times the upper limit of the reference range are allowed. At the discretion of the investigator, transaminase levels >5 times the upper limit of the reference range and γGT >10 times the upper limit of the reference range can be allowed if considered habitual for the patient, either confirmed by patient records or a repeat measurement during the Screening Period
  • The patient has a breath alcohol concentration (BrAC) \<0.02% at the Screening Visit.
  • The patient provides a stable address and telephone number
  • The patient is a man or woman, aged ≥ 18 years
  • The patient has ≤30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • The patient has any psychiatric disorder or Axis I disorder (™ criteria), established as the primary diagnosis, other than alcohol dependence assessed using the Mini International Neuropsychiatric Interview (MINI) or another diagnostic interview , that in any way will interfere with the ability of the patient to take part in the study
  • The patient has reported current use of, or has been tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines [including ecstasy], barbiturates)
  • The patient has severe liver impairment classified with a Score C
  • The patient has one or more clinical laboratory test values outside the reference range, based on the blood and urine samples taken at the Screening Visit, that are of potential risk to the patient's safety, or the patient has: Severe renal impairment ( \<30 mL/min per 1.73 m2), and/or Hypercholesterolemia with serum cholesterol levels > 300 mg/dL, (>7,758 mmol/L), and/or > 3 mg/dL (50 μmol/L)
  • The patient has had \<6 heavy drinking days (HDDs, defined by the European Medicines Agency as a day with an alcohol consumption >60 g for men or >40 g for women) in the 4 weeks preceding the Screening Visit
  • The patient has >5 consecutive abstinence days in the 4 weeks preceding the Screening Visit
  • The patient has a recent history of acute alcohol withdrawal syndrome (including hallucinations, seizures, or delirium tremens)

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Selincro® (nalmefene) 18 mg, tablets

    One tablet orally for 12 weeks on days when the patient perceives a risk of drinking alcohol, preferably 1-2 hours prior to the anticipated risk of drinking.

    Drug: nalmefene

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the number of heavy drinking days per month (HDDs) (days/month)

    Time frame: Baseline to months 1, 2 and 3

  2. Change from baseline in the number of HDDs per week (days/week)

    Time frame: Baseline to weeks 1 and 2

  3. Change from baseline in total alcohol consumption (TAC) (g alcohol/day)

    Time frame: Baseline to months 1, 2 and 3

  4. Change from baseline in TAC (g alcohol/day)

    Time frame: Baseline to weeks 1 and 2

  5. Response Shift Drinking Risk Level (RSDRL)

    Defined as a downward shift from baseline in drinking risk level (DRL); for patients with a very high DRL at baseline, a shift to medium DRL or lower; for patients with a high DRL at baseline, a shift to low DRL or below

    Time frame: Baseline to month 3

  6. Response Low Drinking Risk Level (RLDRL)

    Defined as a downward shift from baseline in DRL to low DRL or below

    Time frame: Baseline to month 3

  7. Response defined as ≥70% reduction in TAC

    Time frame: Baseline to month 3

  8. Response defined as 0 to 4 HDDs (days/month)

    Time frame: Month 3

  9. Clinical Global Impression, global improvement (CGI-I).

    Time frame: Weeks 4 and 12

  10. Change from baseline in Clinical Global Impression, Severity of illness (CGI-S)

    Time frame: Baseline to weeks 4 and 12

  11. Change in the Short-Form 36-Item Health Survey (SF-36)

    Time frame: Baseline to week 12

  12. Change in liver stiffness

    Time frame: Baseline to weeks 1,2 4 and 12

  13. Category shift in fibrosis stage

    Time frame: Baseline to weeks 1,2 4, and 12

  14. Change in transaminases and γ-glutamyl transferase (γGT)

    Time frame: Baseline to weeks 1,2,4,8, and 12

  15. Change in bilirubin, albumin, and International Normalized Ratio (INR)

    Time frame: Baseline to weeks 1,2,4,8, and 12

  16. Number of adverse events

    Time frame: Screening to week 14

07

Study locations

3 sites
  • DE001
    Heidelberg, Germany
  • DE002
    Mannheim, Germany
  • Optuminisight
    München, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014 and a primary completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2014
First posted
Jul 22, 2014
Start
Sep 2014
Primary completionActual
Dec 2015
Last update
Dec 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02197598
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jul 22, 2014
Start date
Sep 2014
Primary completion
Dec 2015
Last update
Dec 14, 2016

Study contacts

Email contact via H.Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion